Answers are grounded in this paper and cite their sources.
Case report demonstrates accelerated cardiac rhabdomyoma regression with everolimus in a neonate with refractory heart failure, highlighting the therapeutic utility of mTOR inhibitors.
Cardiac Rhabdomyomas (CR) are a rare occurrence with an incidence of 0.1% and are the most common primary cardiac tumors in the fetus and pediatric age groups. Although largely known as “spontaneously regressing tumor” very rarely they cause symptoms of heart failure due to ventricular dysfunction or outflow tract obstruction, or arrhythmias. When associated with tuberous sclerosis complex (TSC) they are usually multiple in number. mTOR inhibitors were recently approved by FDA for the treatment of TSC. We report a case of fetal and neonatal rhabdomyoma presenting as heart failure refractory to medical management and was treated with mTOR inhibitors (Everolimus) with which the patient had improvement in symptoms and accelerated regression of tumor. We conclude that rhabdomyomas though asymptomatic in most, can present with refractory heart failure and mTOR inhibitors can be helpful in such cases.
No takes yet. Share an insight, caveat, or question.
Prasad et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: